Previous 10 | Next 10 |
Specalty medical-device maker PAVmed (NASDAQ: PAVM) didn't make for a great stock on Wednesday. The company's shares were rocked by an investor sell-off that sent their price down by nearly 13%. This followed the announcement of a new financing effort. PAVmed filed a shelf-regis...
Shares of PAVmed (PAVM -13.8%) are down today after the company filed for a $275M mixed shelf offering after the closing bell yesterday. The company says proceeds will be used for working capital and other general corporate purposes. The medical devices company is focused on medical infusion,...
Gainers: BiondVax (NASDAQ:BVXV) +96%. SeaChange (NASDAQ:SEAC) +46%. Acasti (NASDAQ:ACST) +43%. Society Pass (NASDAQ:SOPA) +30%. ALJ Regional Holdings (NASDAQ:ALJJ) +26%. Red Cat (OTCQB:RCAT) +23%. Getnet Adquirencia (NASDAQ:GET) +23%. Lottery (NASDAQ:LTRY) +20%. Bellerophon Therapeutics (NASD...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid, office-based EsoGuard testing to detect esophageal precancer before it progresses to deadly cancer Lucid Diagnostics...
Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...
Shares of Lucid Diagnostics (LUCD -18.9%) are down sharply today after the company reported that its Q3 2021 net loss widened ~244% to ~$7M (-$0.49 net loss per share, basic and diluted). Operating expenses increased ~225% to ~$6.6M. The company has just $200K in revenue for the quarter due t...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief Financial Offi...
PAVmed Inc. (PAVM) Q3 2021 Earnings Conference Call November 16, 2021, 04:30 PM ET Company Participants Lisa DeScenza - VP, Integrated Communications at LaVoieHealthScience Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Kyle Mikson - Canaccord ...
Shares of PAVmed (NASDAQ:PAVM) are down 10% in after-hours trading after the company's Q3 2021 earnings results missed estimates on revenue, while EPS was in-line. On a non-GAAP basis, the company's net loss widened ~121% to ~$12.3M (-$0.10 per share adjusted). Operating expenses in...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...